19-288: Neoadjuvant TSR-042 (dostarlimab) for Patients with Rectal Adenocarcinoma

Condition: Rectal Cancer

Sponsor: Memorial Sloan Kettering Cancer Center

Full Title
Protocol 19-288: A Phase II Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors

Eligibility
Stage II - III mismatch repair deficient or microsatellite instability high rectal adenocarcinoma eligible to receive neoadjuvant therapy.

Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.

Locations
Central Park Medical Oncology
Eastchester Cancer Center
Port Jefferson Medical Oncology